TELO News & Events

Telomir Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer, TNBC.

Telomir Pharmaceuticals announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals. The transaction, which was approved by Telomir's shareholders at the Company's Annual Meeting held on March 23, 2026, establishes Telomir as the sole holder of the global rights of Telomir-1.

elomir Pharmaceuticals announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1, for the treatment of advanced and metastatic Triple-Negative Breast Cancer. The IND submission includes data from completed IND-enabling pharmacology, toxicology, and manufacturing studies. Subject to IND clearance, the Company plans to initiate a Phase 1/2 clinical trial evaluating Telomir-1 as an oral monotherapy in patients with advanced or metastatic TNBC. Subject to IND clearance, Telomir plans to initiate its Phase 1/2 clinical trial in advanced TNBC and continue advancing biomarker-driven development strategies. In parallel, the Company is continuing to expand its preclinical program, including evaluation of Telomir-Zn in additional TNBC animal models and further characterization of its mechanism of action. The Company has submitted scientific manuscripts to peer-reviewed journals and plans to present data at scientific conferences, including the AACR Annual Meeting 2026.